Toggle the Real-time protection switch off. You may receive a User Account Control (UAC) prompt asking if you want to allow the change to occur. Select Yes. When you're ready to turn system protection ...

SentinelOne’s Singularity Platform achieves GovRAMP Authorization, High Impact level, providing a standardized approach to assessing cloud products.

Radware ® (NASDAQ: RDWR), a global leader in application security and delivery solutions for multi-cloud environments, today announced the discovery of ZombieAgent, a new zero-click indirect prompt ...

Enterprise Strategy Group’s most recent research revealed that SaaS applications are not immune to data loss. In fact, 53% of respondents reported SaaS data loss or corruption over a 12‑month period.

Background Complex breast surgery, including immediate breast reconstruction and oncoplastic procedures, is increasingly performed to optimise oncologic and aesthetic outcomes. Postoperative wound ...

KuCoin has published its 2025 Annual Review, and the tone is noticeably different from past years. Titled “A Renewed Brand. A ...

Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.

Acronis, a global leader in cybersecurity and data protection, is accelerating security momentum across the cybersecurity industry with AI-powered product innovation, deep threat intelligence, and ...

The Duke of Sussex has reportedly won a Home Office review of his police security detail when visiting the UK. Prince Harry was furious when the Royal and VIP Executive Committee (RAVEC) removed his ...

From BYOD to ransomware, you need to cover all your endpoint bases Chances are, the number of endpoints in your organization has exploded in the past few years. Between BYOD, remote work and the sheer ...

John Breeden II is an award-winning reviewer with more than 20 years of experience covering technology. Follow him on Twitter @TheLabGuys. Higher education institutions handle a lot of sensitive ...

Shares of Neuphoria Therapeutics were trading in the red in the after-hours session Monday, as the company announced a strategic review following news BNC210 anti-anxiety drug didn't meet the primary ...